I just read this article published in the New York Times, April 10, 2018.
nytimes.com/2018/04/09/well...
The next to the last paragraph is probably most pertinent to us. I'm sure it hasn't been tested on people with PMR yet but perhaps with other AI disorders or on immunosuppressant medications.
This is an article from last November that talks more about people in immunosuppressed states. nytimes.com/2017/11/10/heal...
This article out of Canada has more details comparing people who took Shingrix vs Placebo under the Clinical Trials section.
ca.gsk.com/media/1350788/sh...
I found the discussion of adverse events most germaine.
Potential Immune-Mediated DiseasesIn studies ZOE-50 and ZOE-70, new onset of potential immune-mediated diseases (pIMDs) or exacerbation of existing pIMDs were reported for 1.2% of subjects who received SHINGRIX and 1.4% of subjects who received placebo during the entire follow-up period (median 4.4 years, range: 0 to 5.0 years). Approximately half of pIMDs occurred with time to onset longer than one year after the last vaccination. The most frequently reported pIMDs in the vaccine and placebo groups were polymyalgia rheumatica (0.2% in each group), rheumatoid arthritis (0.1% versus 0.2%, respectively), psoriasis (0.1% in each group), and autoimmune thyroiditis (0.1% in each group).
I think it is worthwhile discussing with my Rheumy. I had chicken pox at 18 months, and Herpes Zoster at age 22 in my middle ear. So I know it is lurking.....I had the older vaccine when it came out, but I suspect I'm susceptible. Not sure I want to rock the PMR boat right now, but if I read this correctly, there was no difference between Shingrix and Placebo groups over the four years tested.